Joseph Tung-Chieh CHANG MD, MHA

Proton therapy

Proton Therapy. Head and Neck Cancer. Nasopharyngeal cancer Radiotherapy, Breast cancer, Hepatoma, GI cancer, Health related Quality of life research, Patient Decision Making Sharing and Coaching

Specialty

Proton Therapy. Head and Neck Cancer. Nasopharyngeal cancer Radiotherapy, Breast cancer, Hepatoma, GI cancer, Health related Quality of life research, Patient Decision Making Sharing and Coaching


Profile

Joseph Tung-Chieh Chang, MD,MHA, is a board-certified radiation oncologist, sub-specializing in head and neck cancer especially for nasopharyngeal carcinoma, breast cancer and gastrointestinal cancers. He is the chairman of the Department of Radiation Oncology and Director of Proton and Radiation Therapy Center, Chang Gung Memorial Hospital (CGMH) at Linkou. The department is the largest in the nation. The proton facility will serve the patients since fall of 2015. The first MRI-simulator in Taiwan starts in Spring of 2016.
 
Dr. Chang got his MD degree at Taipei Medical College in 1989 and master of health administration in Chang Gung University in 2003. He completed his 4-year residency training at Chang Gung Memorial Hospital, got the clinic professor in 2008 and became the chairman of the department in 2014. He and his colleges have dedicated their lives to the research and development of cancer radiation treatments, particularly in the subject of head and neck cance, nasopharyngeal carcinoma, breast cancer, health related quality of life and liver cancer. Up to date, Dr. Chang has successfully treated over 8,000 patients and published more than 200 peer-reviewed papers.  

He does not only an active member of Taiwan and international clinical professional societies but also a member in Psycho-social societies. Dr. Chang does not only emphasize in cancer control but also put his effort in the issue of life quality. He wants his patients live in good life but not only long life.


Successful Cases

More than thousand cases of head and neck cancer (including nasopharyngeal cancer patients). The achievement do not provide the patients with tumor control but better health related quality of life for patients.

Education

1982 - 1989, MD, Medicine, Taipei Medical University. Taipei, Taiwan

1998 - 2002  MHA, Health Care Management, Chang Gung University, Taiwan


Past Experiences

Visiting Scholar in M.D. Anderson Cancer Center

Visiting Scholar in Memorial Sloan-Kettering Cancer Center

Executive Director for Taoyuan Physician Association


Current Appointments

Professor, Dept. Chief & Director, Department of Radiation Oncology, Proton and Radiation Therapy Center, Chang Gung Memorial Hospital.

Board Member of Steering Committee for Particle Therapy Co-Operative Group

Member of Head and Neck subcommittee of NRG

Executive Director for Taiwan Society for Therapeutic Radiology and Oncology

Awards 

Research Award of National Science Council


Medical Contributions

The first physician who practice proton therapy for head and neck cancer in Taiwan and South East Asia.

The first tier radiation oncologist who performed intensity modulation radiotherapy and volume modulated radiotherapy for head and neck cancer

The number of individual papers has exceeded 200. The papers of the first and corresponding authors from 2016 to 2020 are listed below.

*Corresponding author

  1. Fan KH, Chao YK, Chang JT*, Tsang NM, Liao CT, Chang KP, Lin CY, Wang HM, Hsu CL, Huang SF. (2019, 08) A retrospective analysis of the treatment results for advanced synchronous head and neck and esophageal cancer. BJR|Open. https://doi.org/10.1259/bjro.20190015.
  2. Li YC, Cheng AJ, Lee LY, Huang YC, Chang JT*. (2019, 07) Multifaceted Mechanisms of Areca Nuts in Oral Carcinogenesis: the Molecular Pathology from Precancerous Condition to Malignant Transformation. J Cancer. 10(17):4054-4062.
  3. You GR, Cheng AJ, Lee LY, Huang YC, Liu H, Chen YJ, Chang JT*. (2019, 01) Prognostic signature associated with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses. BMC Cancer. 14;19(1):64.
  4. Huang PW, Lin CY, Hsieh CH, Hsu CL, Fan KH, Huang SF, Liao CT, Ng SK, Yen TC, Chang JT*, Wang HM*. (2018, 04) A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx. Biomed J. 41(2):129-136.(共同通訊作者)
  5. Fan KH, Chen YC, Lin CY, Kang CJ, Lee LY, Huang SF, Liao CT, Ng SH, Wang HM, Chang JT*. (2017, 11) Postoperative radiotherapy with or without concurrent chemotherapy for oral squamous cell carcinoma in patients with three or more minor risk factors: a propensity score matching analysis. Radiat Oncol. 22;12(1):184.
  6. Hung TM, Lin CR, Chi YC, Lin CY, Chen EY, Kang CJ, Huang SF, Juang YY, Huang CY*, Chang JT*. (2017, 8) Body image in head and neck cancer patients treated with radiotherapy: the impact of surgical procedures. Health Qual Life Outcomes. 15(1):165. (共同通訊作者)
  7. Lu YC, Cheng AJ, Lee LY, You GR, Li YL, Chen HY, Chang JT*. (2017, 5) MiR-520b as a novel molecular target for suppressing stemness phenotype of head-neck cancer by inhibiting CD44. Sci Rep. 7(1):2042.
  8. Hung TM, Fan KH, Chen EY, Lin CY, Kang CJ, Huang SF, Liao CT, Ng SH, Wang HM, Chang JT* (2017, 2) An elective radiation dose of 46 Gy is feasible in nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a long-term follow-up result. Medicine (Baltimore). 96(6):e6036.
  9. Li YL, Chang JT, Lee LY, Fan KH, Lu YC, Li YC, Chiang CH, Chen HY, Cheng AJ*. (2017. 1) GDF15 contributes to radioresistance and cancer stemness of head and neck cancer by regulating cellular oreactive oxygen species via a SMAD-associated signaling pathway. Oncotarget.  8(1):1508-1528. (共同第一作者)
  10. Chiang CH, Wu CC, Lee LY, Li YC, Liu HP, Hsu CW, Lu YC, Chang JT*, Cheng AJ*. (2016, 9) Proteomics Analysis Reveals Involvement of Krt17 in Areca Nut-Induced Oral Carcinogenesis. J Proteome Res. 15(9):2981-97. (共同指導作者)
  11. Huang BS, Chen WY, Hsieh CE, Lin CY, Lee LY, Fang KH, Tsang NM, Kang CJ, Wang　HM, Chang JT*.(2016,　9) Outcomes and prognostic factors for surgery followed by modern radiation therapy in parotid gland carcinomas. Jpn J Clin Oncol. 46(9):832-8.
  12. Li YC, Chang JT, Chiu C, Lu YC, Li YL, Chiang CH, You GR, Lee LY, Cheng AJ*. (2016, 5) Areca nut contributes to oral malignancy through facilitating the conversion of cancer stem cells. Mol Carcinog. 55(5):1012-23. doi: 10.1002/mc.22344. Epub 2015 Jun 18. (共同第一作者)
  13. Lu YC, Chang JT, Chan EC, Chao YK, Yeh TS, Chen JS, Cheng AJ*. (2016, 3) miR-196, an emerging cancer biomarker for digestive tract cancers. J Cancer. 7(6):650-5. doi: 10.7150/jca.13460. eCollection 2016. (共同第一作者)